In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
New Science Market Intelligence Innovation

Snapshot: June Highlights

  • Data

Executive Summary

A selection of articles you might have missed from June 2022, including a deep dive into venture finance, an in depth discussion about Russia's upcoming drug supply woes, and the latest Rising Leaders interviews.

You may also be interested in...



GE Finalizes Details Of GE HealthCare Spin-Off

Over four years in the making, the deal will spin-off General Electric’s health care business into a separate public company.

Boston Scientific Makes Half Billion Dollar GI Endosurgery Play

Boston Scientific is greatly increasing its GI endosurgery capabilities with the acquisition of Apollo Endosurgery, a manufacturer of various device for weight loss-related surgeries.

Digital Health Roundup: HLTH2022 Highlights, EU Updates, Diabetes Medtech Monthly

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb provides highlights from the recent HLTH conference in Las Vegas. Reed Miller and Barnaby Pickering offer an overview of the highly competitive diabetes tech market. We also talk about digital health in Germany and Europe.

Table

View full table

Topics

Tags:
New Science Market Intelligence Innovation
Latest News

RNA Medicines: Advancements Leading To Investments

Lessons From Novo Nordisk’s Mads Øvlisen, The Father Of CSR

The Busiest Dealmakers Of 2022

Clinical Trials: Have We Finally Reached The New Normal?

See All
UsernamePublicRestriction

Register

IV125128

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By